Los Angeles Capital Management & Equity Research Inc. Takes Position in Emergent Biosolutions, Inc. (EBS)

Los Angeles Capital Management & Equity Research Inc. Takes Position in Emergent Biosolutions, Inc. (EBS)

Los Angeles Capital Management & Equity Research Inc. acquired a new position in Emergent Biosolutions, Inc. (NYSE:EBS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,573 shares of the biopharmaceutical company’s stock, valued at approximately $207,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Emergent Biosolutions by 13.0% in the second quarter. Vanguard Group Inc. now owns 3,610,132 shares of the biopharmaceutical company’s stock worth $101,517,000 after buying an additional 415,470 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Emergent Biosolutions by 4.3% in the second quarter. Dimensional Fund Advisors LP now owns 2,149,815 shares of the biopharmaceutical company’s stock worth $60,453,000 after buying an additional 88,071 shares during the last quarter. Acadian Asset Management LLC increased its stake in Emergent Biosolutions by 1.1% in the third quarter. Acadian Asset Management LLC now owns 1,604,001 shares of the biopharmaceutical company’s stock worth $50,573,000 after buying an additional 16,798 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Emergent Biosolutions by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 866,851 shares of the biopharmaceutical company’s stock worth $24,376,000 after buying an additional 20,226 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in Emergent Biosolutions by 40.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 739,287 shares of the biopharmaceutical company’s stock valued at $20,789,000 after buying an additional 211,936 shares in the last quarter. 89.33% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions, Inc. (NYSE:EBS) traded down 0.86% during trading on Friday, hitting $30.11. The stock had a trading volume of 178,219 shares. Emergent Biosolutions, Inc. has a 12 month low of $24.47 and a 12 month high of $44.38. The company’s 50 day moving average is $32.24 and its 200-day moving average is $29.72. The company has a market cap of $1.22 billion, a PE ratio of 28.51 and a beta of 1.01.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.32. The company had revenue of $142.91 million for the quarter, compared to the consensus estimate of $112.30 million. Emergent Biosolutions had a return on equity of 10.42% and a net margin of 9.12%. Emergent Biosolutions’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.93 earnings per share. On average, equities research analysts predict that Emergent Biosolutions, Inc. will post $1.06 earnings per share for the current year.

Several equities analysts have recently weighed in on EBS shares. Wells Fargo & Company set a $41.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a research report on Saturday, October 1st. Chardan Capital set a $47.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a research report on Saturday, December 10th. Zacks Investment Research raised Emergent Biosolutions from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Finally, Cowen and Company reissued a “hold” rating on shares of Emergent Biosolutions in a research report on Monday, January 9th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $39.40.

In other Emergent Biosolutions news, Director Ronald Richard sold 5,900 shares of the stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $34.09, for a total transaction of $201,131.00. Following the transaction, the director now owns 19,870 shares in the company, valued at $677,368.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Adam Havey sold 8,438 shares of the stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $29.75, for a total value of $251,030.50. Following the transaction, the executive vice president now owns 41,424 shares in the company, valued at approximately $1,232,364. The disclosure for this sale can be found here. Insiders have sold 62,002 shares of company stock worth $1,913,955 in the last quarter. 17.20% of the stock is currently owned by company insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Related posts

Leave a Comment